You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-21. Gender ratio by primary drug — ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2006 [see all tables in this series...]

Part (iii) Ratio of males to females among new clients entering inpatient treatment

Country		Opioids	Cocaine	Stimulants	Hypnotics and sedatives	Hallucinogens	Volatile substances	Cannabis	Other drugs	Base (known status)
Bulgaria	(1)	5.7								177
Czech Republic	(2)	1.8		1.4	0.4	1.0	3.0	2.4	0.0	825
Denmark	(3)	2.0						2.6		56
Germany	(4)	3.9	10.5	36.0	1.0			3.8	5.9	461
Ireland	(5)	3.4	7.0	9.0	2.0			6.4	0.0	502
Greece	(6)	5.4	4.8	2.0	4.0			3.4	1.0	806
France		10.5			1.5			9.0		42
Cyprus	(7)	6.0						1.0		20
Latvia	(8)	3.2		2.7	1.5			6.8	4.0	362
Hungary	(9)	3.2	4.5	1.3	0.5	8.0	2.8	6.8	1.4	1302
Austria	(10)	1.9	2.8	0.0	2.0			15.0		171
Slovakia		3.8		4.4	0.4		4.3	3.9		241
Finland	(11)	1.6		1.8	1.9			2.7		142
Sweden		1.7		1.7	1.3	3.0		4.4	2.2	616
United Kingdom		2.6	3.0	1.4	2.8			1.6	2.0	1115
Turkey		20.4	12.0	11.6	4.0		38.0	28.2	5.0	1495
Total		3.6	5.0	1.9	0.6	8.3	12.0	7.1	2.6	2.8
Total base		3388	487	1171	1179	28	259	1648	173	8333

Notes:

(1) No female cases for cocaine and hypnotics; no cases for hallucinogens, volatile substances and other drugs.

(2) No female cases for cocaine.

(3) No cases for hallucinogens, volatile substances and other drugs.

(4) No female cases for hallucinogens; no cases for Volatile substances and other drugs.

(5) No female cases for stimulants; no cases for hallucinogens, volatile substances and other drugs.

(6) No female cases for cocaine and cannabis; no cases for stimulants, hypnotics, hallucinogens, volatile substances and other drugs.

(7) No cases for hallucinogens.

(8) No female cases for hallucinogens.

(9) No female cases for other drugs; no cases for cocaine and hallucinogens.

(10) No female cases for hallucinogens and volatile substances.

(11) No female cases for other drugs; no cases for hallucinogens.

See also 'General notes for interpreting data’ on the Explanatory notes and help page.

Sources:

Reitox national reports 2007 — TDI — inpatient treatment centres.

Download this data in Excel (.xls) format

(see the help page for information about formats etc.)